Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.

Article Details

Citation
Copy to clipboard

Galmarini CM

Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.

Curr Opin Investig Drugs. 2006 Dec;7(12):1108-15.

PubMed ID
17209529 [ View in PubMed
]
Abstract

Biomira Inc, following its acquisition of ProlX Pharmaceutical Corp, is developing PX-12, an inhibitor of thioredoxin, for the potential treatment of cancer. PX-12 has completed phase I clinical trials.

DrugBank Data that Cites this Article

Drugs